KEY POINTS
- This prospective, randomized, double-blind trial from Far Eastern Memorial Hospital, Taiwan, compared three single-fraction postoperative electron radiotherapy doses after keloid excision. Of 96 enrolled patients, 88 completed treatment and were analyzed: 30 received 9 Gy, 29 received 11 Gy, and 29 received 13 Gy. Both patients and outcome-assessing physicians were blinded to dose assignment. The primary endpoint was local control at 12 months, with scar severity and quality of life assessed as secondary outcomes.
- All patients received postoperative radiotherapy within 24 hours of excision, using 6-MeV electrons with a 1.5-cm margin around the surgical scar. Dose was prescribed to the 90% isodose line, with 5-mm bolus for auricular lesions and 3-mm bolus for other anatomical sites. Anatomical locations were prospectively categorized as high tension, including anterior chest, shoulder, suprapubic region, and upper extremities, or low tension, including earlobes and other minimally stressed sites. Postoperative silicone-based gel treatment was standardized.
- Twelve-month recurrence decreased numerically with increasing radiation dose. Local recurrence occurred in 7/30 patients (23.3%) after 9 Gy, 5/29 (17.2%) after 11 Gy, and 2/29 (6.9%) after 13 Gy. The absolute recurrence difference between 9 Gy and 13 Gy was 16.4 percentage points. However, the primary three-group comparison was not statistically significant (p=0.192), and no Bonferroni-adjusted pairwise comparison reached significance. Recurrence-free survival also did not differ significantly (log-rank p=0.245).
- Multivariable analysis suggested an independent association between lower dose and recurrence. After adjusting for lesion width and anatomical tension, 9 Gy versus 13 Gy was associated with higher recurrence odds (OR 5.7, 95% CI 1.0–32.3; p=0.046). The comparison between 9 Gy and 11 Gy was not significant (OR 2.2; p=0.260). Although this adjusted result supports a possible dose-response relationship, the wide confidence interval and negative primary analysis warrant caution.
- Anatomical tissue tension appeared to influence recurrence risk. Recurrence occurred in 13/66 high-tension lesions (19.7%) versus 1/22 low-tension lesions (4.5%; p=0.082). Within high-tension sites, recurrence decreased from 33.3% after 9 Gy to 8.7% after 13 Gy, although the comparison of 13 Gy against pooled lower doses did not reach statistical significance (log-rank p=0.112). The single recurrence in the low-tension subgroup prevented meaningful survival modeling or validation of a lower-dose strategy.
- Objective scar outcomes favored 13 Gy despite similar patient-reported quality of life. At 12 months, adjusted modified Vancouver Scar Scale scores were 2.29 after 13 Gy, versus 5.95 after 11 Gy and 5.90 after 9 Gy (p<0.001 for both comparisons). Radiation dose significantly affected longitudinal scar severity (p=0.001), while Skindex-16 quality-of-life scores did not differ significantly (overall dose effect p=0.527). An exploratory modified Vancouver Scar Scale cutoff of ≥7 identified recurrence with AUC 0.93, but requires external validation.
- Severe acute toxicity was uncommon, but long-term safety remains uncertain. Grade 2 adverse events occurred in 3/88 patients (3.4%), including one radiation dermatitis event and two delayed wound-healing events. No grade ≥3 toxicity was reported. The 12-month follow-up was insufficient to assess delayed skin changes or rare radiation-induced malignancies, and no standard multifraction postoperative RT comparator was included. The trial was also limited by only 14 recurrence events and modest baseline imbalances in lesion characteristics.
CLINICAL TAKEAWAY
A single postoperative fraction of 13 Gy produced the lowest observed keloid recurrence rate and significantly better objective scar outcomes compared with lower doses. However, the primary randomized comparison was nonsignificant, and the apparent advantage at high-tension sites remains exploratory. Larger randomized studies with longer follow-up and comparisons against established multifraction schedules are needed before adopting 13 Gy as a universal postoperative standard.
SOURCE
International Journal of Radiation Oncology, Biology, Physics